{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:22:53Z","timestamp":1788452573493,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":239,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2018\/05616-3"],"award-info":[{"award-number":["2018\/05616-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["133851\/2019-2"],"award-info":[{"award-number":["133851\/2019-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.clinsp.2024.100491","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T15:45:04Z","timestamp":1727106304000},"page":"100491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Changes in fluconazole pharmacokinetics can impact on antifungal effectiveness in critically ill burn patients: a Pharmacokinetic-Pharmacodynamic (PK\/PD) approach"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2079-4568","authenticated-orcid":false,"given":"Victor Kaneko","family":"Matsuno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edvaldo Vieira de","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elson Mendes da","family":"Silva Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Manoel da","family":"Silva Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David de Souza","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Regina Cavani Jorge","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clinsp.2024.100491_bib0001","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.burns.2016.08.013","article-title":"Recent trends in burn epidemiology worldwide: A systematic review","volume":"43","author":"Smolle","year":"2017","journal-title":"Burns"},{"key":"10.1016\/j.clinsp.2024.100491_bib0002","unstructured":"World Health Organization (WHO). Fact sheets \u2013 Burns. 2018. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/burns. [Accessed December 15th, 2019]."},{"issue":"9","key":"10.1016\/j.clinsp.2024.100491_bib0003","doi-asserted-by":"crossref","first-page":"790","DOI":"10.7603\/s40730-016-0040-6","article-title":"Mortality rate associated with hospital acquired infections among burn patients","volume":"3","author":"Bharwana","year":"2016","journal-title":"Biomed Res Ther"},{"issue":"2","key":"10.1016\/j.clinsp.2024.100491_bib0004","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1089\/sur.2013.134","article-title":"Infection in Burns","volume":"17","author":"Norbury","year":"2016","journal-title":"Surg Infect (Larchmt)."},{"key":"10.1016\/j.clinsp.2024.100491_bib0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12281-011-0047-9","article-title":"Antifungal Pharmacokinetics and Dosing Considerations in Burn Patients","volume":"5","author":"Walraven","year":"2011","journal-title":"Curr Fungal Infect Rep"},{"issue":"8","key":"10.1016\/j.clinsp.2024.100491_bib0006","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1128\/JCM.00773-06","article-title":"Epidemiology of candidemia in Brazil: A nationwide sentinel surveillance of candidemia in eleven medical centers","volume":"44","author":"Colombo","year":"2006","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.clinsp.2024.100491_bib0007","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.bjid.2013.02.001","article-title":"Brazilian guidelines for the management of candidiasis \u2013 a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical","volume":"17","author":"Colombo","year":"2013","journal-title":"Braz J Infect Dis"},{"issue":"4","key":"10.1016\/j.clinsp.2024.100491_bib0008","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"CID"},{"issue":"1","key":"10.1016\/j.clinsp.2024.100491_bib0009","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1128\/AAC.03935-14","article-title":"Stratification of the impact of inappropriate empirical antimicrobial therapy for Gram-negative bloodstream infections by predicted prognosis","volume":"59","author":"Cain","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.clinsp.2024.100491_bib0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","article-title":"Applications of the pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of antimicrobial agents","volume":"21","author":"Asin-Prieto","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.clinsp.2024.100491_bib0011","unstructured":"World Health Organization (WHO). Improving the prevention, diagnosis and clinical management of sepsis - Seventieth World Health Assembly. 2017. Available from: http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA70\/A70_R7-en.pdf. [Accessed December 15th, 2019]."},{"issue":"10","key":"10.1016\/j.clinsp.2024.100491_bib0012","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2165\/00003088-200847100-00002","article-title":"Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients","volume":"47","author":"Blanchet","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.clinsp.2024.100491_bib0013","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/ALN.0000000000000559","article-title":"Acute and perioperative care of the burn-injured patient","volume":"122","author":"Bittner","year":"2015","journal-title":"Anesthesiology"},{"issue":"3","key":"10.1016\/j.clinsp.2024.100491_bib0014","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.burns.2012.07.005","article-title":"Individualised vancomycin doses for paediatric burn patients to achieve PK\/PD targets","volume":"39","author":"Gomez","year":"2013","journal-title":"Burns"},{"issue":"3","key":"10.1016\/j.clinsp.2024.100491_bib0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/ja.2014.121","article-title":"Imipenem in burn patients: Pharmacokinetic profile and PK\/PD target attainment","volume":"68","author":"Gomez","year":"2015","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.clinsp.2024.100491_bib0016","first-page":"806","volume":"2","author":"Santos","year":"2015","journal-title":"Badajoz: Formatex Research Center"},{"issue":"Suppl 2","key":"10.1016\/j.clinsp.2024.100491_bib0017","first-page":"32","article-title":"Meropenem effectiveness in septic burn patients by comparison of extended infusion versus fast infusion against susceptible strains based on drug plasma measurements done in a real time","volume":"21","author":"Silva","year":"2017","journal-title":"Crit Care"},{"issue":"Suppl 2","key":"10.1016\/j.clinsp.2024.100491_bib0018","first-page":"31","article-title":"Piperacillin effectiveness in septic burn patients by comparison of two empirical daily dose regimen recommended 12 versus 16g against susceptible strains based on drug plasma measurements done in a real time","volume":"21","author":"Silva","year":"2017","journal-title":"Crit. Care."},{"issue":"2","key":"10.1016\/j.clinsp.2024.100491_bib0019","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1590\/S1807-59322010000200017","article-title":"Fluconazole plasma concentration measurement by liquid chromatography for drug monitoring of burn patients","volume":"65","author":"Santos","year":"2010","journal-title":"Clinics"},{"key":"10.1016\/j.clinsp.2024.100491_bib0020","series-title":"Concepts in Clinical Pharmacokinetics","author":"Dipiro","year":"2010"},{"issue":"5","key":"10.1016\/j.clinsp.2024.100491_bib0021","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1128\/AAC.42.5.1105","article-title":"Pharmacodynamics of Fluconazole in a Murine Model of Systemic Candidiasis","volume":"42","author":"Louie","year":"1998","journal-title":"Antimicrobl Agents and Chemother"},{"issue":"9","key":"10.1016\/j.clinsp.2024.100491_bib0022","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/AAC.43.9.2116","article-title":"Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model","volume":"43","author":"Andes","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.clinsp.2024.100491_bib0023","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1128\/AAC.28.5.648","article-title":"Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans","volume":"28","author":"Humphrey","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinsp.2024.100491_bib0024","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1749-6632.1988.tb40440.x","article-title":"Steady state parenteral kinetics of fluconazole in man","volume":"544","author":"Foulds","year":"1988","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.clinsp.2024.100491_bib0025","first-page":"206","article-title":"Safety and pharmacokinetics of single oral and intravenous doses of fluconazole in healthy subjects","volume":"12","author":"Shiba","year":"1990","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinsp.2024.100491_bib0026","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2125.1990.tb03623.x","article-title":"An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole","volume":"29","author":"Toon","year":"1990","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.clinsp.2024.100491_bib0027","first-page":"6","article-title":"Pharmacokinetics of fluconazole in normal volunteers","volume":"39","author":"Ripa","year":"1993","journal-title":"Chemotherapy"},{"key":"10.1016\/j.clinsp.2024.100491_bib0028","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2125.1994.tb04325.x","article-title":"The pharmacokinetics of fluconazole after a single intravenous dose in AIDS patients","volume":"38","author":"Yeats","year":"1994","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.clinsp.2024.100491_bib0029","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2710.2009.01097.x","article-title":"The pharmacokinetics of fluconazole in healthy Chinese adult volunteers: influence of ethnicity and gender","volume":"35","author":"Guo","year":"2010","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"10.1016\/j.clinsp.2024.100491_bib0030","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1128\/AAC.42.4.930","article-title":"Fluconazole Pharmacokinetics in Burn Patients","volume":"42","author":"Boucher","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.clinsp.2024.100491_bib0031","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1128\/AAC.01372-12","article-title":"Population Pharmacokinetic Analysis of Fluconazole To Predict Therapeutic Outcome in Burn Patients with Candida Infection","volume":"57","author":"Han","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.clinsp.2024.100491_bib0032","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2165\/00044011-200727120-00007","article-title":"Gender differences in the oral pharmacokinetics of fluconazole","volume":"27","author":"Carrasco-Portugal","year":"2007","journal-title":"Clin Drug Invest"},{"issue":"3","key":"10.1016\/j.clinsp.2024.100491_bib0033","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1093\/clinids\/12.Supplement_3.S318","article-title":"Pharmacokinetics and Tissue Penetration of Fluconazole in Humans","volume":"12","author":"Brammer","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.clinsp.2024.100491_bib0034","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-2230.1993.tb00987.x","article-title":"Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat","volume":"18","author":"Faergemann","year":"1993","journal-title":"Clin Exp Dermatology"},{"key":"10.1016\/j.clinsp.2024.100491_bib0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2340\/000155557575361363","article-title":"Intracutaneous Transport of Orally Administered Fluconazole to the Stratum Corneum","volume":"75","author":"Faergemann","year":"1995","journal-title":"Acta Derm Venereol (Stockh)"},{"issue":"I","key":"10.1016\/j.clinsp.2024.100491_bib0036","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2165\/00003088-199733010-00005","article-title":"Clinical Pharmacokinetics of Fluconazole in Superficial and Systemic Mycoses","volume":"33","author":"Debruyne","year":"1997","journal-title":"Clin Pharmocokinet."},{"key":"10.1016\/j.clinsp.2024.100491_bib0037","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0190-9622(99)70393-2","article-title":"Pharmacokinetics of fluconazole in skin and nails","volume":"40","author":"Faergemann","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.clinsp.2024.100491_bib0038","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2133.1990.tb01870.x","article-title":"Fluconazole levels in human epidermis and blister fluid","volume":"123","author":"Haneke","year":"1990","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.clinsp.2024.100491_bib0039","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/000456328502200411","article-title":"The Effects of Septic Complications upon the Serum Protein Changes Associated with Thermal Injury","volume":"22","author":"Moody","year":"1985","journal-title":"Ann Clin Biochem"},{"issue":"5","key":"10.1016\/j.clinsp.2024.100491_bib0040","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00004630-198909000-00010","article-title":"The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries","volume":"10","author":"Zokufa","year":"1989","journal-title":"J Burn Care Rehabil"},{"issue":"7","key":"10.1016\/j.clinsp.2024.100491_bib0041","first-page":"361","article-title":"Protein binding of itraconazole and fluconazole in patients with chronic renal failure","volume":"32","author":"Arredondo","year":"1994","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.clinsp.2024.100491_bib0042","first-page":"449","article-title":"Protein binding of itraconazole and fluconazole in patients with cancer","volume":"33","author":"Arredondo","year":"1995","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"14","key":"10.1016\/j.clinsp.2024.100491_bib0043","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200241140-00002","article-title":"Pharmacokinetic and Pharmacodynamic Considerations When Treating Patients with Sepsis and Septic Shock","volume":"41","author":"De Paepe","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.clinsp.2024.100491_bib0044","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jcrc.2015.04.007","article-title":"\u03b1-1-Acid glycoprotein as a biomarker for the early diagnosis and monitoring the prognosis of sepsis","volume":"30","author":"Xiao","year":"2015","journal-title":"J Crit Care"},{"issue":"6","key":"10.1016\/j.clinsp.2024.100491_bib0045","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2165\/00003088-198611060-00003","article-title":"Free Drug Concentration Monitoring in Clinical Practice Rationale and Current Status","volume":"11","author":"Svensson","year":"1986","journal-title":"Clin Pharmacokinet"},{"issue":"1-2","key":"10.1016\/j.clinsp.2024.100491_bib0046","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0167-4838(00)00153-9","article-title":"Alpha-1-acid glycoprotein","volume":"1482","author":"Fournier","year":"2000","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"10.1016\/j.clinsp.2024.100491_bib0047","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2174\/1389203720666190405101138","article-title":"The Immune Functions of \u03b1 1 Acid Glycoprotein","volume":"20","author":"Ceciliani","year":"2019","journal-title":"Curr Protein Pept Sci"},{"issue":"2","key":"10.1016\/j.clinsp.2024.100491_bib0048","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11095-018-2551-x","article-title":"Pharmacokinetic and Pharmacodynamic Considerations for Drugs Binding to Alpha-1-Acid Glycoprotein","volume":"36","author":"Smith","year":"2019","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.clinsp.2024.100491_bib0049","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00005373-199202000-00022","article-title":"The effects of burn injury on the acute phase response","volume":"32","author":"Xia","year":"1992","journal-title":"J Trauma"},{"issue":"4","key":"10.1016\/j.clinsp.2024.100491_bib0050","first-page":"199","article-title":"Alpha 1-antitrypsin and alpha 1-acid glycoprotein reduce the sensitivity of human dermal fibroblast to endotoxin","volume":"4","author":"Xia","year":"2001","journal-title":"Chin J Traumatol"},{"issue":"6","key":"10.1016\/j.clinsp.2024.100491_bib0051","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/00005373-197006000-00008","article-title":"The turnover rate of orosomucoid in burned patients","volume":"10","author":"Zeineh","year":"1970","journal-title":"J Trauma"},{"issue":"2","key":"10.1016\/j.clinsp.2024.100491_bib0052","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2165\/00003088-199018020-00003","article-title":"Pathophysiology and Pharmacokinetics Following Burn Injury","volume":"18","author":"Bonate","year":"1990","journal-title":"Clin Pharmacokinet."}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593224001686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593224001686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:37:34Z","timestamp":1778827054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593224001686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":52,"alternative-id":["S1807593224001686"],"URL":"https:\/\/doi.org\/10.1016\/j.clinsp.2024.100491","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in fluconazole pharmacokinetics can impact on antifungal effectiveness in critically ill burn patients: a Pharmacokinetic-Pharmacodynamic (PK\/PD) approach","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinsp.2024.100491","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 HCFMUSP. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100491"}}